A sensitive and reliable LC-MS/MS method was developed for measuring apixaban and its metabolite in human plasma, achieving a lower limit of quantification of 1.00 ng/ml for apixaban.
BACKGROUND: apixaban (BMS-562247) (Eliquis(®)) is a novel, orally active, selective, direct, reversible inhibitor of the coagulation factor Xa (FXa). A sensitive and reliable method was developed and validated for the measurement of apixaban (BMS-562247) and its major circulating metabolite (BMS-730823) in human citrated plasma for use in clinical testing. METHODOLOGY/RESULTS: A 0.100 ml portion of citrated plasma sample was extracted and analyzed by LC-MS/MS. Run times were approximately 3 min. The lower limit of quantification (LLOQ) was 1.00 ng/ml for BMS-562247 and 5.00 ng/ml for BMS-730823. Intra- and inter-assay precision values for replicate QC control samples were within ≤5.36% for both analytes (≤7.52% at the LLOQ). The accuracy for both analytes was within ±9.00%. CONCLUSION: The method was demonstrated to be sensitive, selective and robust, and was successfully used to support clinical studies.
Pursley et al. (Fri,) reported a other. LC-MS/MS method was evaluated on Measurement of apixaban and its major circulating metabolite (BMS-730823). A sensitive and reliable LC-MS/MS method was developed for measuring apixaban and its metabolite in human plasma, achieving a lower limit of quantification of 1.00 ng/ml for apixaban.